{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:52:40Z","timestamp":1777711960484,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.pharma.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T17:35:20Z","timestamp":1529775320000},"page":"391-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["La r\u00e9trocession, une activit\u00e9 rentable mais \u00e0 risques"],"prefix":"10.1016","volume":"76","author":[{"given":"D.","family":"Laoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hallouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Remy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bougle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Monzat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bounoure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2018.05.001_bib0085","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). Les \u00e9v\u00e8nements qui ne devraient jamais arriver \u2014\u00a0\u00ab\u00a0Never Events\u00a0\u00bb\u00a0\u2014 ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 n.d. http:\/\/www.ansm.sante.fr\/Dossiers\/Securite-du-medicament-a-l-hopital\/Les-evenements-qui-ne-devraient-jamais-arriver-Never-Events\/(offset)\/0 [accessed April 20, 2016]."},{"key":"10.1016\/j.pharma.2018.05.001_bib0090","unstructured":"Article L.\u00a05126-4\u00a0du Code de sant\u00e9 publique."},{"key":"10.1016\/j.pharma.2018.05.001_bib0095","unstructured":"Article R.\u00a05126-104\u00a0du Code de sant\u00e9 publique."},{"key":"10.1016\/j.pharma.2018.05.001_bib0100","unstructured":"Celgene. R\u00e9sum\u00e9 caract\u00e9ristique du produit du Thalidomide. http:\/\/www.ec.europa.eu\/health\/documents\/community-register\/2015\/20151119133509\/anx_133509_fr.pdf [consult\u00e9 le 20\u00a0avril 2016]."},{"key":"10.1016\/j.pharma.2018.05.001_bib0105","series-title":"\u00c9volution r\u00e9cente des d\u00e9penses de r\u00e9trocession hospitali\u00e8re\u00a0\u2013\u00a0Les Comptes de la S\u00e9curit\u00e9 sociale","author":"S\u00e9curit\u00e9 sociale","year":"2015"},{"key":"10.1016\/j.pharma.2018.05.001_bib0110","series-title":"Gestion des stocks et des magasins\u00a0: pratiques des m\u00e9thodes logistiques adapt\u00e9es au lean manufacturing","author":"Mocellin","year":"2011"},{"key":"10.1016\/j.pharma.2018.05.001_bib0115","series-title":"R\u00e9trocession hospitali\u00e8re ou dispensation officinale\u00a0: comment faciliter l\u2019orientation des patients","author":"Dupuis","year":"2016"},{"key":"10.1016\/j.pharma.2018.05.001_bib0120","first-page":"345","article-title":"S\u00e9curisation des antibioth\u00e9rapies intraveineuses au point de transition h\u00f4pital\/ville\u00a0: \u00e9tat des lieux et plan de communication","volume":"51","author":"Darry","year":"2016","journal-title":"Pharm Hosp Clin"},{"key":"10.1016\/j.pharma.2018.05.001_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pharma.2014.11.001","article-title":"Interventions des pharmaciens sur les prescriptions ambulatoires dans le cadre de l\u2019activit\u00e9 de r\u00e9trocession d\u2019un centre hospitalier universitaire","volume":"73","author":"Chappuy","year":"2015","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2018.05.001_bib0130","year":"2004"},{"key":"10.1016\/j.pharma.2018.05.001_bib0135","year":"2016","journal-title":"JORF"},{"key":"10.1016\/j.pharma.2018.05.001_bib0140","unstructured":"Article R.\u00a04235-48\u00a0du Code de sant\u00e9 publique."},{"key":"10.1016\/j.pharma.2018.05.001_bib0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.meddro.2012.04.001","article-title":"La dispensation de m\u00e9dicaments en France. Partie I\u00a0: \u00e9tat des lieux de la r\u00e9glementation applicable","volume":"116","author":"Hallouard","year":"2012","journal-title":"Med Droit"},{"key":"10.1016\/j.pharma.2018.05.001_bib0150","first-page":"383","article-title":"Place du dossier pharmaceutique parmi les autres sources disponibles sur les traitements des patients \u00e0 leur arriv\u00e9e aux urgences","volume":"52","author":"Nucci","year":"2017","journal-title":"Pharm Hosp Clin"},{"key":"10.1016\/j.pharma.2018.05.001_bib0155","series-title":"Donn\u00e9es r\u00e9gionales\u00a0\u2013\u00a0Le Dossier pharmaceutique","author":"Ordre national des pharmaciens","year":"2015"},{"key":"10.1016\/j.pharma.2018.05.001_bib0080","unstructured":"http:\/\/www.omedit-normandie.fr\/boite-a-outils\/retrocession\/retrocession.2541.2914.html [consult\u00e9 le 18\u00a0avril 2018]."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450918300348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450918300348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:46Z","timestamp":1757720026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450918300348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0003450918300348"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2018.05.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La r\u00e9trocession, une activit\u00e9 rentable mais \u00e0 risques","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}